FDA Approves Mirdametinib for Adult and Paediatric Patients with NF1 Who Have Symptomatic Plexiform Neurofibromas Not Amenable to Complete Resection By Ogkologos - March 20, 2025 642 0 Facebook Twitter Google+ Pinterest WhatsApp Evidence for efficacy is based on the results from the ReNeu study Source RELATED ARTICLESMORE FROM AUTHOR FDA Approves Niraparib and Abiraterone Acetate Plus Prednisone for BRCA2-mutated Metastatic Castration-Sensitive Prostate Cancer The Legacy of the ESMO Patient Engagement Summit 2025: Advancing Rights of Patients with Cancer via Cross-Border Best Practices and Collaboration Sustained PFS Benefit of Imlunestrant Over SoC in Patients with ESR1-mutated Advanced Breast Cancer MOST POPULAR Prostate Cancer Genomics in Racial Minority Groups February 18, 2021 Health inequalities: breaking down barriers to cancer screening September 23, 2022 Study Identifies a Potential Cause of Immunotherapy’s Heart-Related Side Effects December 22, 2022 Trastuzumab Emtansine Improves OS with Sustained Improvement in iDFS Among Patients... January 22, 2025 Load more HOT NEWS Turning the Life Sciences Vision into reality FDA Approves Neoadjuvant/Adjuvant Pembrolizumab for Resectable Non-Small Cell Lung Cancer Company Gives Cancer Patient a New HVAC System After Treatment and... 5 Kids Battling Sickle Cell And Cancer Model Their Dream Jobs...
